A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of XXXX @entity3 .

@entity5 @entity19 @entity320 @entity3
UNASSIGNED: Abstract Tumor @entity3 is the biggest challenge in @entity5 therapy. During the @entity3 process, metastatic cells could acquire stealth ability toward immune system through the formation of a protection cloak by hijacking platelets (PTs). Heparins, a heterogeneous mixture of glycosaminoglycans, can inhibit metastatic cascades by blocking P-selectin-mediated intercellular adhesion between @entity5 cells and PTs. In this study, low-molecular-weight heparin-coated doxorubicin-loaded liposome (LMWH-DOX-Lip) was developed for @entity3 preventative therapy. The formation of LMWH-DOX-Lip was based on electrostatic interactions between the negatively charged heparins and cationic lipids. LMWH-DOX-Lip prepared at the optimum prescription possessed high entrapment efficiency, ideal particle size and zeta potential. Morphology of LMWH-DOX-Lip was characterized by atomic force microscopy and transmission electron microscopy. The results of confocal microscopic observations and flow cytometry analysis indicated that LMWH-DOX-Lip mediated an efficient cellular uptake in @entity19 @entity320 cell line. Besides, LMWH-DOX-Lip displayed an increased cytotoxic over their unmodified counterparts. Furthermore, the inhibition effect of LMWH-DOX-Lip on adhesion between @entity5 cells and PTs/P-selectin was observed. In vivo study performed on a @entity320 @entity19 model revealed a substantially @entity5 @entity3 prevention by LMWH-DOX-Lip. All these results suggested that LMWH-DOX-Lip could significantly inhibit @entity3 through preventing the @entity5 cell-platelet interactions and in the meantime suppressed @entity5 growth.
